Transitions,Introductions,and a Notable Announcement From the US FDA in December 2016

Abstract

Get full access to this article

View all access options for this article.

References

FDA News Release, December 2, 2016. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm. Accessed January 2, 2017.

FDA News Release, August 1, 2014. FDA approves Jardiance to treat type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm. Accessed January 2, 2017.

Meigs

. Epidemiology of cardiovascular complications in type 2 diabetes. Acta Diabetol. 2003;40:S358–S361.

FDA. Guidance for Industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Published December 2008. Accessed January 2, 2017.

Geiger

Mehta

Turner

. Clinical development approaches and statistical methodologies to prospectively assess the cardiovascular risk of new antidiabetic therapies for type 2 diabetes. Ther Innov Regul Sci. 2015;49:50–64.

Zinman

Wanner

Lachin

; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.

Scirica

Bhatt

Braunwald

; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.

Turner

. Key Statistical Concepts in Clinical Trials for Pharma. New York, NY: Springer; 2012.

FDA. Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting, June 28, 2016. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm518911.pdf. Accessed January 2, 2017.

10.

Wanner

Inzucchi

Lachin

; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.

11.

Marso

Daniels

Brown-Frandsen

; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.

12.

Marso

Bain

Consoli

; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.

13.

Turner

Caveney

Gillespie

. Letter to the Editor. With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs. Euro Heart J Cardiovasc Pharmacother. In press.

14.

MacIsaac

Jerums

Ekinci

. Cardio-renal protection with empagliflozin. Ann Transl Med. 2016;4:409.